Higher Incidence of Cancer Therapy-Related Cardiac Dysfunction in the COVID-19 Era: A Single Cardio-Oncology Center Experience

COVID-19 pandemic had a big impact on our life, it has revolutionized the practice of cardiology and the organization of hospital and outpatient activities. Thus the aim of our study was to assess the impact of the COVID-19 pandemic on the development of cancer therapy-related cardiac dysfunction (C...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cardiovascular development and disease 2023-01, Vol.10 (1), p.23
Main Authors: Di Lisi, Daniela, Madaudo, Cristina, Di Fazio, Luca, Gulotta, Antonino, Triolo, Oreste Fabio, Galassi, Alfredo Ruggero, Incorvaia, Lorena, Russo, Antonio, Novo, Giuseppina
Format: Article
Language:English
Subjects:
Anthracyclines
Biomarkers
Breast cancer
Cancer
Cancer therapies
cardio-oncology
Cardiology
Cardiotoxicity
Care and treatment
Chemotherapy
Coronaviruses
COVID-19
CTRCD
Development and progression
Disease transmission
Drug dosages
Electrocardiography
Epidemics
Health aspects
Heart attacks
Heart failure
Hypertension
Kinases
Oncology
Oncology, Experimental
pandemic
Pandemics
Patients
Surveillance
Telemedicine
Ultrasonic imaging
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:COVID-19 pandemic had a big impact on our life, it has revolutionized the practice of cardiology and the organization of hospital and outpatient activities. Thus the aim of our study was to assess the impact of the COVID-19 pandemic on the development of cancer therapy-related cardiac dysfunction (CTRCD). A single center retrospective study was carried out evaluating 96 cancer patients treated with anthracyclines and admitted to our Cardio-Oncology unit from June to August 2019 and 60 patients from June to August 2021. The incidence of CTRCD was assessed performing an echocardiogram at the time of the enrollment. We found a significantly higher incidence of CTRCD in the second period compared to first period (13% vs. 2%, value 0.0058). In addition we found that fewer yearly visits were performed in our Cardio-oncology unit in 2021 compared to 2019 (300 patients/year in 2019 vs. 144 patients/year in the COVID era). COVID-19 pandemic seems to influence the onset of CTRCD in cancer patients by indirectly reducing hospital access of cancer patients and cardiological checks. In addition our data reflect the impact of the COVID-19 pandemic in the late diagnosis of cancer, in the reduction of hospital admissions and regular medical checks, in the increase of comorbidities and cardiovascular complications.
ISSN:2308-3425
2308-3425
DOI:10.3390/jcdd10010023